A review of data recorded in the National Health Interview Survey showed that cost-related nonadherence with medication decreased in stroke survivors following the implementation of the ACA.
The FDA has approved Invokana (canagliflozin) to reduce the risk of major CV events.
Investigators observed a significant association between atrial fibrillation and increasing oxygen desaturation index.
A culturally tailored, skills-based educational intervention did not reduce systolic blood pressure at one year after stroke/transient ischemic attack.
Variations in published stroke rates for patients with AF not receiving anticoagulants result in differences in the calculated net clinical benefit of anticoagulation.
There is variation in the net clinical benefit of anticoagulants based on variation in published atrial fibrillation stroke rates.
The primary outcome was an unfavorable neurologic outcome, which was defined as a modified Rankin Scale score of 3 to 6 at 3 months following randomization.
Preoperative statin therapy is associated with higher long-term survival following abdominal aortic aneurysm repair.
Mortality benefits from atorvastatin- and amlodipine-based antihypertensive treatments extend beyond 10 years of treatment.
Psychological distress had a dose-dependent, positive association with myocardial infarction and stroke in men and women.
Among adult survivors of stroke, Medicaid costs increased while nonadherence costs decreased after Affordable Care Act implementation.
The UK FAST campaign attempted to bolster patient response to both transient ischemic attack and minor stroke.
Local ischemia after an acute ischemic stroke may trigger a widely migrating cortical wave of spreading depolarization, which may present as migraine aura.
Stroke risk 19% lower with breastfeeding for 1 to 6 months, and there was a stronger link for longer duration.
Patients with atrial fibrillation who have ≥1 non-sex CHA2DS2VASc stroke risk factor should receive oral anticoagulation as antithrombotic therapy.
In this randomized controlled trial, administration of alteplase within 3 hours of mild stoke did not lead to a reduction in disability at 90 days following stroke compared with aspirin.
In this cluster-randomized clinical trial, quality improvement interventions led to slightly greater adherence of evidence-based, performance measures compared with usual care for acute ischemic stroke management in China.
Patients with atrial fibrillation who take NSAIDs in addition to oral anticoagulants may have an increased risk for major bleeding and stroke.
Ultra-early neurological deterioration was seen most often in patients with intracranial hemorrhage patients and tied to worse 3-month outcomes.
Apixaban demonstrated superiority over warfarin in terms of reducing the risk for major bleeding in patients with atrial fibrillation and end-stage kidney disease who were on dialysis.
PFO closure plus antiplatelets recommended over antiplatelet therapy alone for patients younger than 60 years.
Although COPD has been identified as a risk factor for cardiovascular disease, researchers are less certain about the relationship between COPD and stroke.
The apparent increase in risk for hemorrhagic stroke among patients with previous infective endocarditis was explained by the mediating factors of mechanical heart valve insertion, atrial fibrillation, and anticoagulation medication.
There was a similar magnitude of risk in men and women, independent of depression.
Stroke risk remained significantly lower after PCI than after CABG at 5-year follow-up.
Apixaban reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin.
More pronounced differences in venous thromboembolism and ischemic stroke in individuals who initiated hormone treatment during follow-up.
High-risk APOL1 genotype was linked to HFpEF hospitalization in postmenopausal black women.
An association was seen between marital status and risk and prognosis of coronary heart disease or stroke.
The rate of a composite of stroke, acute coronary syndrome, or death from cardiovascular causes occurred in 12.9% of patients; 50.1% of events occurring in the second to fifth years.
The Cardiology Advisor Articles
- Should Guidelines Use Higher Risk Thresholds When Recommending Statins for Primary CVD Prevention?
- Ezetimibe Plus Statins Modestly Reduce Cardiovascular Disease Event Risk
- ACC, AHA Publish Appropriate Use Criteria Guidelines for Peripheral Artery Intervention
- FDA: E-Liquids Found to Contain Undeclared Sildenafil and Tadalafil
- Ultrasound-Based Visualization of Silent Atherosclerosis May Improve Medication Adherence
- ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD
- Childhood Behavioral Interventions May Promote Adult Cardiovascular Health
- US Medical Schools Increase in Diversity After Implementation of Accreditation Standards
- Botox Injections Explored to Reduce Postop AF in Cardiac Surgery
- AHA Scientific Statement: Low Risk of Side Effects With Statins
- Do More Aggressive Periprocedural Antibiotic Regimens Reduce Risk of Device-Related Infections?
- Adherence and Intensity of Lipid-Lowering Therapy Influence CV Risk
- Challenges in Weighing Costs, Therapeutic Benefits of Expensive Pharmaceuticals
- Sustained Systolic Blood Pressure Reductions With Barbershop Intervention
- Stethoscopes in ICU Show High Levels of Bacterial Contamination